We are using combinations of genome-wide assays and biochemistry to study how transcription factors select their binding sites in the context of nuclear chromatin.

We are studying the establishiment & function of epigenetic marks in normal myeloid development and leukemia using genome-wide technologies and functional approaches.

We aim at understanding the role of cohesin and its mutations in hematopoiesis & leukemia using advanced genome-wide approaches to map the genome in three dimensions.

We are leveraging genome-wide technologies and bioinformatics analysis to understand transcriptional networks controlling the therapeutic efficacy of regulatory T cells.

We apply mouse models and genetic engineering to understand the impact of DNA methylation on metastatic progression.

We use genetic and epigentic screens to identify mechanisms behind interindividual epigenetic variation.